These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32348525)

  • 1. Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.
    Cid MC; Ríos-Garcés R; Terrades-García N; Espígol-Frigolé G
    Rheumatology (Oxford); 2020 May; 59(Suppl 3):iii17-iii27. PubMed ID: 32348525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
    Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Therapeutic Approaches to Large-Vessel Vasculitis.
    Kaymakci MS; Warrington KJ; Kermani TA
    Annu Rev Med; 2024 Jan; 75():427-442. PubMed ID: 37683286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Need and value of targeted immunosuppressive therapy in giant cell arteritis.
    Sandovici M; van der Geest N; van Sleen Y; Brouwer E
    RMD Open; 2022 Feb; 8(1):. PubMed ID: 35149602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of giant cell arteritis: what is in the pipeline?].
    Holle JU; Moosig F
    Z Rheumatol; 2020 Aug; 79(6):516-522. PubMed ID: 32399619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of giant cell arteritis.
    González-Gay MÁ; Pina T; Prieto-Peña D; Calderon-Goercke M; Gualillo O; Castañeda S
    Biochem Pharmacol; 2019 Jul; 165():230-239. PubMed ID: 31034796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic Therapies for Giant Cell Arteritis.
    Harrington R; Al Nokhatha SA; Conway R
    Biologics; 2021; 15():17-29. PubMed ID: 33442231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Giant cell arteritis: what is new in the preclinical and early clinical development pipeline?
    Harkins P; Conway R
    Expert Opin Investig Drugs; 2022 Sep; 31(9):921-932. PubMed ID: 34106030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of biologics in the treatment of giant cell arteritis.
    González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S
    Expert Opin Biol Ther; 2019 Jan; 19(1):65-72. PubMed ID: 30513026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.
    Régent A; Redeker S; Deroux A; Kieffer P; Ly KH; Dougados M; Liozon E; Larroche C; Guillevin L; Bouillet L; Espitia O; Costedoat-Chalumeau N; Soubrier M; Brihaye B; Lifermann F; Lefevre G; Puéchal X; Mouthon L; Toussirot E;
    J Rheumatol; 2016 Aug; 43(8):1547-52. PubMed ID: 27182063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biotherapies in large vessel vasculitis.
    Ferfar Y; Mirault T; Desbois AC; Comarmond C; Messas E; Savey L; Domont F; Cacoub P; Saadoun D
    Autoimmun Rev; 2016 Jun; 15(6):544-51. PubMed ID: 26883459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients.
    Calderón-Goercke M; Castañeda S; Aldasoro V; Villa I; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; De Miguel E; Prieto-Peña D; González-Gay MÁ; Hernández JL; Blanco R;
    Semin Arthritis Rheum; 2021 Apr; 51(2):387-394. PubMed ID: 33607384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging diagnosis tools and therapeutics for giant cell arteritis.
    González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S
    Expert Rev Clin Immunol; 2018 Jul; 14(7):593-605. PubMed ID: 29877748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological treatments in giant cell arteritis & Takayasu arteritis.
    Samson M; Espígol-Frigolé G; Terrades-García N; Prieto-González S; Corbera-Bellalta M; Alba-Rovira R; Hernández-Rodríguez J; Audia S; Bonnotte B; Cid MC
    Eur J Intern Med; 2018 Apr; 50():12-19. PubMed ID: 29146018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic treatment of large-vessel vasculitides.
    Schäfer VS; Zwerina J
    Curr Opin Rheumatol; 2012 Jan; 24(1):31-7. PubMed ID: 22089099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab in the treatment of giant cell arteritis.
    Leuchten N; Aringer M
    Immunotherapy; 2018 Mar; 10(6):465-472. PubMed ID: 29504436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab for giant cell arteritis: an amazing result.
    Işık M; Kılıç L; Doğan İ; Calgüneri M
    Rheumatol Int; 2013 Nov; 33(11):2961-2. PubMed ID: 22965672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis.
    Matteson EL; Buttgereit F; Dejaco C; Dasgupta B
    Rheum Dis Clin North Am; 2016 Feb; 42(1):75-90, viii. PubMed ID: 26611552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic approach to giant cell arteritis.
    Masson C
    Joint Bone Spine; 2012 May; 79(3):219-27. PubMed ID: 22119350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [From pathogenesis of giant cell arteritis to new therapeutic targets].
    Samson M; Bonnotte B
    Rev Med Interne; 2017 Oct; 38(10):670-678. PubMed ID: 28800947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.